300122 智飞生物
2026/03 - 三个月
人民币(K¥)
2025/12
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
经营活动产生之现金流量净额278,0695,167,320(4,413,989)8,996,3701,989,033
投资活动产生之现金流量净额(102,091)(594,942)(925,583)(976,599)(1,497,955)
筹资活动产生之现金流量净额(1,075,251)(4,732,800)1,697,887(4,293,867)(2,172,647)
汇率变动对现金及现金等价物的影响(16,912)(687)1,252(2,303)17,557
现金及现金等价物净增加/(减少)(916,184)(161,109)(3,640,434)3,723,601(1,664,012)
期初现金及现金等价物余额2,542,9602,704,0696,339,2902,615,6894,279,701
期末现金及现金等价物余额1,626,7762,542,9602,698,8566,339,2902,615,689